Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
23 November 2021 - 12:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on
transforming medicines to transform lives, announced today that
Greg Divis, Chief Executive Officer of Avadel, will participate in
the following upcoming investor conferences:
- Piper Sandler 33rd
Annual Virtual Healthcare Conference: Participation starting on
Monday, November 29 with a Fireside chat available for on-demand
viewing starting today, Monday, November 22 at 10:00 a.m. ET.
- Evercore ISI 4th
Annual HealthCONx Conference: Fireside chat on Wednesday, December
1 at 2:00 p.m. E.T.
A webcast of these events, as well as archived recordings, will
be available on Avadel’s Investor Relations website,
investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical
company focused on transforming medicines to transform lives. Our
approach includes applying innovative solutions to the development
of medications that address the challenges patients face with
current treatment options. Our current lead drug candidate, FT218,
is an investigational formulation of sodium oxybate leveraging our
proprietary drug delivery technology and designed to be taken once
at bedtime for the treatment of excessive daytime sleepiness and
cataplexy in adults with narcolepsy. For more information, please
visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Nicole Raisch GoelzReal
Chemistryngoelz@realchemistry.com (408) 568-4292
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2023 to Apr 2024